Effect of Digital Health Coaching on Self-Efficacy and Patient-Reported Outcomes in Individuals with Acute Myeloid and Chronic Lymphocytic Leukemia: A Pilot Randomized Controlled Trial
Acta Haematologica · 2024
DOI: 10.1159/000539756 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Acta Haematologica, 2024. Verfasst von Jennifer Marvin-Peek und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, jmarvin@mdanderson.org. Hauptthemen laut MEDLINE: Self Efficacy, Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Patient Reported Outcome Measures. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Digitalisierung in der Pflege
Abstract (Originalsprache)
Introduction
Promotion of self-efficacy can enhance engagement with health care and treatment adherence in patients with cancer. We report the outcomes of a pilot trial of a digital health coach intervention in patients with leukemia with the aim of improving self-efficacy.
Methods
Adult patients with newly diagnosed acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) were randomized 1:1 to a digital health coach intervention or standard of care. The primary outcome of self-efficacy was measured by the Cancer Behavior Inventory (CBI) score.
Results
A total of 147 patients (37 AML, 110 CLL) were enrolled from July 2020 to December 2022. In the AML cohort, there was a mean increase in CBI score of 7.03 in the digital health coaching arm compared to a mean decrease of −3.57 in the control arm at 30 days (p = 0.219). There were no significant associations between the intervention and other patient-reported outcomes for patients with CLL.
Conclusion
There were numerical, but not statistically significant increases in self-efficacy metrics in AML patients who received digital health coaching. Although this trial was underpowered due to enrollment limitations during a pandemic, digital health coaching may provide benefit to patients with hematologic malignancy and warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, jmarvin@mdanderson.org.
- Department of Nursing, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Pack Health, A Quest Diagnostics Company, Birmingham, Alabama, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Marvin-Peek, J., Shelton, V., Brassil, K., Fellman, B., Barr, A., Chien, K. S., Hammond, D., Swaminathan, M., Jain, N., Wierda, W., Ferrajoli, A., & DiNardo, C. (2024). Effect of Digital Health Coaching on Self-Efficacy and Patient-Reported Outcomes in Individuals with Acute Myeloid and Chronic Lymphocytic Leukemia: A Pilot Randomized Controlled Trial. Acta Haematologica. https://doi.org/10.1159/000539756
Vancouver
Marvin-Peek J, Shelton V, Brassil K, Fellman B, Barr A, Chien KS, et al. Effect of Digital Health Coaching on Self-Efficacy and Patient-Reported Outcomes in Individuals with Acute Myeloid and Chronic Lymphocytic Leukemia: A Pilot Randomized Controlled Trial. Acta Haematologica. 2024. doi:10.1159/000539756
BibTeX
@article{MarvinPeek2024,
author = {Marvin-Peek, Jennifer and Shelton, Valerie and Brassil, Kelly and Fellman, Bryan and Barr, Austin and Chien, Kelly Sharon and Hammond, Danielle and Swaminathan, Mahesh and Jain, Nitin and Wierda, William and Ferrajoli, Alessandra and DiNardo, Courtney},
title = {Effect of Digital Health Coaching on Self-Efficacy and Patient-Reported Outcomes in Individuals with Acute Myeloid and Chronic Lymphocytic Leukemia: A Pilot Randomized Controlled Trial},
journal = {Acta Haematologica},
year = {2024},
doi = {10.1159/000539756}
}
EUVIMED